The prognostic value of NRF2 in solid tumor patients: a meta-analysis

Lingling Wang, Chunze Zhang, Litao Qin, Jingyue Xu, Xiaobo Li, Wenhong Wang, Lingqin Kong, Taizhen Zhou and Xichuan Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:1257-1265. https://doi.org/10.18632/oncotarget.19838

Metrics: PDF 1315 views  |   HTML 2275 views  |   ?  


Lingling Wang1,*, Chunze Zhang2,*, Litao Qin3,*, Jingyue Xu4,*, Xiaobo Li1, Wenhong Wang2, Lingqin Kong5, Taizhen Zhou6 and Xichuan Li1

1School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

2Tianjin Union Medical Center, Tianjin, China

3Medical Genetic Institute of Henan Province, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan, China

4Department of Clinical Laboratory, the Fifth Central Hospital of Tianjin, Tianjin, China

5Jining Tumor Hospital, Jining No.1 People's Hospital North Campus, Shandong, China

6Traditional Chinese Medical Hospital of Changle, Shandong, China

*These authors contributed equally to this work

Correspondence to:

Xichuan Li, email: [email protected]

Keywords: solid tumors, NRF2, prognosis, meta-analysis

Received: June 10, 2017     Accepted: July 25, 2017     Published: August 03, 2017


Nuclear factor E2-related factor 2 (NRF2), a transcription factor, is known as a potential therapeutic target of solid tumor for that it is a master regulator of the injury and inflammation response, including controlling antioxidant cell progress. Recent studies showed that NRF2 played significant roles in tumorigenesis and tumor progression, however no association and relationship between NRF2 expression and different clinical manifestation of solid tumor had been accurately evaluated. The present meta-analysis picked up 17 suitable articles from EMBASE, PubMed, and ISI Web of Science databases, including 2238 patients. Combined with results of hazard ratios (HRs) and 95% confidence intervals (CIs), we concluded that a higher expression of NRF2 would have worse impact on overall survival (HR = 2.29, 95% CI 1.80–2.91, P < 0.05) and disease-free survival (HR = 2.34, 95% CI 1.36–4.00, P < 0.05) by a random-effect model. Moreover, further results were positively correlated to the clinical diagnosis, curative effect observation and prognosis, including tumor differentiation, lymph node metastasis, distant metastasis and clinical stage. Consequently, our data shown that NRF2 is a potential poor prognostic factor in a variety of solid tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19838